The effective switch from intensive insulin therapy to the once-daily human GLP-1 analogue liraglutide in patients with fairly well controlled type 2 diabetes
Not Applicable
Recruiting
- Conditions
- type 2 diabetes
- Registration Number
- JPRN-UMIN000005202
- Lead Sponsor
- Department of Diabetes and Endocrinology, Kanto Rosai Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 20
Inclusion Criteria
Not provided
Exclusion Criteria
1, Subjects who have already been treated with oral hypoglycemic agents. 2, Subjects who are hypersensitive to this medicine and/or contaminants of this medicine. 3, Any condition that the investigator considers a potential obstacle to trial participation
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Changes in the parameters related to glucose profile of the subjects and proinsulin to C-peptide ratio before and after switching
- Secondary Outcome Measures
Name Time Method Diabetes treatment satisfaction questionnaire (DTSQ), Frequency of side effects (digestive symptoms, hypoglycemia)